CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter TrialNirali N. Shah, Richard Aplenc, Jeffery J. Auletta et al.|Blood|2023Cited by 62
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Liora M. Schultz et al.|Blood Advances|2025Cited by 15
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AMLSwati Naik, Saar Gill, Richard Aplenc et al.|Blood Advances|2025Cited by 7
Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHISPrakash Satwani, Liora M. Schultz, Karen Chao et al.|Blood|2023Cited by 1
LONG TERM Outcomes of Pediatric Patients with Malignant and NON-Malignant Disorders Receiving Α/Β T-CELL Depleted HLA-Haploidentical Hematopoietic STEM CELL Transplantation (HSCT) Followed by Infusion of BPX-501 T CELLS (DONOR T CELLS Transduced with IC9Swati Naik, Franco Locatelli, Neena Kapoor et al.|Transplantation and Cellular Therapy|2017Cited by 0